{
  "patientId": "22334",
  "demographics": {
    "name": "David Garcia",
    "dob": "1959-04-11",
    "gender": "Male",
    "address": "67 Oak Circle, Anytown, USA, 12345",
    "phone": "555-2233",
    "insurance": "Cigna - Policy #CIG-DG-43210",
    "referringPhysician": "Dr. Mark Johnson (Medical Oncology)",
    "emergencyContact": "Jane Garcia (Wife) - 555-1234 (Relationship: Spouse). Primary contact for all medical updates.",
    "advanceDirectives": "Healthcare Proxy: Jane Garcia (Daughter: Maria Garcia as alternate). Living Will on file. Verified 05/15/2025 during multidisciplinary consult.",
    "supportServices": "Nutritional Counseling (Pre-RT and ongoing for weight management), Social Work Referral (for emotional support, resource navigation, and transportation assistance). Referral to Pancreatic Cancer Action Network (PanCAN) for patient resources. Physical therapy consult for baseline strength assessment and maintenance exercises.",
    "mobility": "Independent, Ambulatory. ECOG Performance Status 1 at baseline. Patient reports feeling stronger after induction chemotherapy."
  },
  "diagnosis": {
    "primary": "Pancreatic Adenocarcinoma",
    "location": "Head of Pancreas",
    "grade": "Moderately Differentiated (Grade 2) Adenocarcinoma",
    "datePathologicDiagnosis": "02/01/2025 (EUS-guided Biopsy)",
    "tumorSize": "3.0 cm (largest dimension on diagnostic imaging)",
    "vascularInvolvement": "Abuts Superior Mesenteric Vein (SMV) for less than 180 degrees circumference. No Superior Mesenteric Artery (SMA) involvement. No celiac axis or hepatic artery involvement. No distant vascular compromise.",
    "pathologicStage": "Borderline Resectable Pancreatic Adenocarcinoma cT2 N0 M0 Stage IB (AJCC 8th Edition). Borderline resectable due to SMV abutment.",
    "symptomsAtPresentation": "Painless jaundice (eyes and skin), dark urine, clay-colored stools (resolved after stent), mild mid-back pain (intermittent), unintentional weight loss (8 lbs over 3 months). No severe abdominal pain or vomiting. No new onset diabetes.",
    "pathologyFindings": [
      "EUS-guided biopsy of pancreatic head mass confirms Adenocarcinoma, moderately differentiated. Specimen shows infiltrating glandular structures with moderate nuclear atypia.",
      "Sampled peripancreatic lymph node (Station 12) negative for malignant cells.",
      "Immunohistochemistry: CK7 positive, CK20 negative, DPC4 retained."
    ],
    "relevantHistory": "No significant past medical history other than type 2 diabetes (well-controlled with oral medications). Denies smoking or heavy alcohol use. Family history: Father had colon cancer (age 70s).",
    "baselineStatus": "ECOG 1 (Ambulatory, restricted in physically strenuous activity but able to perform light daily tasks). KPS 80. Biliary stent effectively relieved jaundice. Pain controlled with acetaminophen. Blood sugar well-controlled.",
    "priorProcedures": "Endoscopic Ultrasound (EUS) with biopsy (02/01/2025). Endoscopic Retrograde Cholangiopancreatography (ERCP) with biliary stent placement (02/05/2025) to relieve obstruction and jaundice.",
    "priorTreatmentSummary": "Completed 4 cycles of FOLFIRINOX (Fluorouracil, Leucovorin, Irinotecan, Oxaliplatin) induction chemotherapy (from 02/15/2025 to 05/10/2025). Tolerated moderately well with manageable GI side effects and neutropenia. Followed by restaging imaging showing tumor response."
  },
  "treatmentPlan": {
    "radOnc": "Dr. Robert Evans",
    "medOnc": "Dr. Mark Johnson",
    "surgOnc": "Dr. Laura Chen (HPB Surgeon)",
    "treatmentSite": "Pancreas Head and surrounding regional lymphatics",
    "intent": "Neoadjuvant (Pre-operative chemoradiation to downstage tumor, convert to resectable, and improve surgical margin negativity)",
    "modality": "External Beam Radiation Therapy (EBRT) with concurrent Chemotherapy (following induction chemo)",
    "rtRxDetails": "50.4 Gy in 28 fractions (1.8 Gy/fx daily, 5 days/week)",
    "targetVolumeSummary": "Gross Tumor Volume (GTV) is pancreatic head mass identified on diagnostic CT/PET. Internal Target Volume (ITV) generated from 4D-CT to account for respiratory motion. Clinical Target Volume (CTV) is ITV + 0.8 cm margin for microscopic disease, including potential draining nodal regions (peri-pancreatic, portacaval, celiac). Planning Target Volume (PTV) is CTV + 0.5 cm setup margin. Critical Organs at Risk (OARs) include kidneys, stomach, duodenum, small bowel, liver, and spinal cord.",
    "techniqueSummary": "Intensity Modulated Radiation Therapy (IMRT) utilizing 7 static fields. Optimized for highly conformal dose delivery to the pancreatic tumor and involved nodes while minimizing dose to surrounding critical abdominal organs. Daily Cone Beam CT (CBCT) guidance used for precision positioning and adaptive planning considerations. Breathing motion managed with 4D-CT ITV approach.",
    "concurrentChemo": "Capecitabine",
    "detailedConcurrentChemo": "Capecitabine 825 mg/m^2 orally twice daily, taken with food, during radiation (Managed by Dr. Johnson). Start 1 day prior to RT. Total planned cycles: 6-7 weeks of daily Capecitabine concurrent with RT.",
    "medications": [
      "Ondansetron 8mg PO PRN Nausea/Vomiting (for acute symptoms)",
      "Loperamide 2mg PO PRN Diarrhea (for acute symptoms)",
      "Pancreatic Enzymes (e.g., Creon 24000 units with meals/snacks) for pancreatic insufficiency (to aid digestion and nutrition)",
      "Antacids/PPI (e.g., Pantoprazole 40mg PO Daily) for heartburn/gastritis prophylaxis (common side effect from RT/chemo)",
      "Insulin/Oral Hypoglycemics (continue current diabetes regimen, monitor blood glucose closely daily during RT)"
    ],
    "therapistAlerts": [
        "High risk for nausea, vomiting, fatigue, and GI side effects (diarrhea, abdominal pain). Monitor daily and report severity. Encourage proactive use of PRN medications.",
        "Assess hydration and nutrition status daily (patient weight, skin turgor, verbal report of intake). Encourage fluid intake and frequent small meals. Provide Ensure/Boost if oral intake is poor.",
        "Patient taking oral chemotherapy (Capecitabine); reinforce compliance instructions (take with food, BID dosing, hand-foot syndrome monitoring) and side effects daily.",
        "Ensure consistent bladder filling (if used in protocol) and abdominal compression for reproducibility and OAR sparing.",
        "Monitor blood glucose levels daily due to diabetes and potential impact of RT/chemo."
    ],
    "gynOnc": "N/A",
    "dermatologist": "N/A"
  },
  "radiationOncologyData": {
    "ctSimulation": {
      "simulationDate": "05/20/2025",
      "setupInstructions": "Supine in custom BodyFix or VacLok bag, with a shallow headrest and knee/ankle immobilization. Abdominal compression with a belly board is used to reduce respiratory motion. Patient instructed on shallow breathing for 4D-CT acquisition. SAD setup with skin marks placed at isocenter projections. Ensure bladder is comfortably full and consistent for daily treatment to push small bowel out of field.",
      "immobilization": "BodyFix or VacLok bag (custom molded for torso), abdominal compression device (belly board), knee/ankle sponge.",
      "referenceMarks": "3-point tattoos placed at isocenter projections (anterior abdominal wall and bilateral laterals). Supplemental marks for visual setup on skin. Isocenter placed at geometric center of PTV.",
      "setupImages": [
        { "type": "AP", "url": "https://placehold.co/250x200/EEE/31343C?text=AP+Setup+Photo_DG22334" },
        { "type": "Lateral", "url": "https://placehold.co/250x200/EEE/31343C?text=Lateral+Setup+Photo_DG22334" }
      ],
      "scanner": "Siemens Somatom go.Up (Integrated 4D-CT capabilities)",
      "sliceThickness": "2.5 mm (for high-resolution planning). 1.5 mm for 4D-CT acquisition to accurately capture respiratory motion.",
      "contrastUsed": "IV Contrast (100ml Omnipaque 300mgI/ml) for tumor and vascular delineation. Oral contrast (Omnipaque 2%) for bowel delineation. Ensure patient had adequate hydration prior to IV contrast.",
      "ctNotes": "4D-CT acquired with immobilization/compression. Respiratory motion assessed (tumor motion ~0.5-1.0 cm in SI direction, managed with ITV). Data acquired for IMRT planning. Fused with diagnostic CT abdomen/pelvis (01/20/2025) for detailed target and OAR delineation. Isocenter placed at geometric center of PTV to optimize beam angles. Patient tolerated setup well. Good compliance with breathing instructions."
    },
    "dosimetry": {
      "planId": "DG22334_Panc_IMRT",
      "planStatus": "Final - Approved by Dr. Robert Evans (05/23/2025)",
      "rx": "50.4 Gy / 28 fx (1.8 Gy/fx daily)",
      "technique": "IMRT (7 static fields, optimized for abdominal anatomy)",
      "energy": "6MV (photon energy)",
      "numberOfFieldsOrArcs": 7,
      "gantryAngles": "0, 51, 102, 153, 204, 255, 306 (Angles chosen to wrap around target while minimizing hot spots and OAR dose)",
      "collAngles": "Variable (optimized by TPS to shape beams to MLC contours)",
      "couchAngles": "0 (Patient supine)",
      "isoCoords": "L0.0, L+8.0, V-5.0 (Lateral, Anterior-Posterior, Superior-Inferior relative to CT sim reference point, fixed at pancreatic head for precise alignment)",
      "tps": "Eclipse 16.1 (Treatment Planning System)",
      "algorithm": "AcurosXB (v16.1.1, advanced algorithm for accurate dose calculation in abdominal region)",
      "hetero": "Yes (Full heterogeneity correction applied for tissue density variations)",
      "norm": "PTV Mean 95% (95% of PTV receives 50.4 Gy)",
      "constraints": "Kidney Mean < 18 Gy (achieved L:15.5 Gy, R:16.0 Gy); Stomach Max < 54 Gy (achieved 50.0 Gy); Duodenum Max < 54 Gy (achieved 51.2 Gy); Small Bowel Max < 54 Gy (achieved 50.5 Gy); Spinal Cord Max < 45 Gy (achieved 38.0 Gy); Liver Mean < 30 Gy (achieved 25.1 Gy). All critical organ constraints met with acceptable clinical margins. Liver V30Gy < 50% (achieved 42%).",
      "planNotes": "Neoadjuvant IMRT for borderline resectable pancreatic cancer. Daily CBCT for IGRT. Avoidance of critical abdominal structures (kidneys, stomach, small bowel, duodenum, liver) was heavily prioritized during optimization due to high toxicity risk. Plan exhibits excellent coverage and conformity. Patient to maintain consistent bladder fill.",
      "igrtProtocol": {
        "frequency": "Daily",
        "type": "Cone Beam CT (CBCT) - Abdominal CBCT",
        "alignment": "Soft tissue match to GTV/pancreas head. Verify stomach, duodenum, and small bowel position relative to PTV. Shifts approved by therapists within pre-set tolerance, physician approval for larger shifts or rotational errors. Bladder fill consistency checked.",
        "tolerances": "Translational: +/- 3mm; Rotational: +/- 1 degree. Action taken for out-of-tolerance shifts (e.g., re-imaging, physician review)."
      },
      "qaChecks": [
        { "date": "2025-05-23", "type": "Initial Chart Check", "by": "Physics Staff (JL)", "result": "Pass - Rx, volumes, constraints, and plan notes verified per protocol. Patient safety reviewed." },
        { "date": "2025-05-23", "type": "Patient Specific QA (Mobius 3D, ArcCHECK)", "by": "Physics Staff (AK)", "result": "Pass (Gamma 99.0% @ 3%/2mm); Absolute dose match within 1.5%." },
        { "date": "2025-05-24", "type": "Weekly Plan Check", "by": "Dosimetrist (MK)", "result": "Pass - Weekly plan review for any significant changes from initial plan. No issues found yet." },
        { "date": "2025-05-24", "type": "Dry Run Verification", "by": "Lead Therapist (SD)", "result": "Pass - Machine parameters, field sequencing, and couch movements verified on LINAC. Patient setup in immobilization confirmed." }
      ],
      "fieldDetails": [
        { "fieldName": "Field 1 (AP)", "fieldSize": "12x14 cm (MLC defined)", "gantryAngle": "0", "collimatorAngle": "0", "couchAngle": "0", "energy": "6MV", "monitorUnits": 62, "ssd": "88.5 cm (Calculated)"},
        { "fieldName": "Field 2 (RAO)", "fieldSize": "12x14 cm (MLC defined)", "gantryAngle": "51", "collimatorAngle": "30", "couchAngle": "0", "energy": "6MV", "monitorUnits": 78, "ssd": "89.0 cm (Calculated)"},
        { "fieldName": "Field 3 (LAO)", "fieldSize": "12x14 cm (MLC defined)", "gantryAngle": "102", "collimatorAngle": "330", "couchAngle": "0", "energy": "6MV", "monitorUnits": 71, "ssd": "90.0 cm (Calculated)"},
        { "fieldName": "Field 4 (Post)", "fieldSize": "12x14 cm (MLC defined)", "gantryAngle": "153", "collimatorAngle": "0", "couchAngle": "0", "energy": "6MV", "monitorUnits": 66, "ssd": "91.5 cm (Calculated)"},
        { "fieldName": "Field 5 (LPO)", "fieldSize": "12x14 cm (MLC defined)", "gantryAngle": "204", "collimatorAngle": "30", "couchAngle": "0", "energy": "6MV", "monitorUnits": 72, "ssd": "90.5 cm (Calculated)"},
        { "fieldName": "Field 6 (RPO)", "fieldSize": "12x14 cm (MLC defined)", "gantryAngle": "255", "collimatorAngle": "330", "couchAngle": "0", "energy": "6MV", "monitorUnits": 77, "ssd": "89.5 cm (Calculated)"},
        { "fieldName": "Field 7 (AP)", "fieldSize": "12x14 cm (MLC defined)", "gantryAngle": "306", "collimatorAngle": "0", "couchAngle": "0", "energy": "6MV", "monitorUnits": 61, "ssd": "88.0 cm (Calculated)"}
      ],
      "imagingFields": [
        { "fieldName": "CBCT (Abdomen)", "gantryAngle": "Full Arc", "fieldSize": "Volume", "energy": "kV", "monitorUnits": "N/A" }
      ]
    },
    "treatmentDelivery": {
      "fractions": [
        {
          "fractionNumber": 1,
          "totalFractions": 28,
          "date": "2025-06-01",
          "machine": "LINAC 2",
          "therapistInitials": "JG, RS",
          "overallMUs": 487,
          "setupVerification": "Adjustments Made",
          "immobilizationDevicesChecked": "BodyFix bag, abdominal compression",
          "setupAdjustments": "V: -0.2 cm, L: 0.1 cm, S: 0 cm shifts applied based on CBCT.",
          "organTargetChecks": "CBCT reviewed, good alignment of pancreas/target after shifts. Bowel position acceptable, outside high dose. Bladder fill consistent.",
          "imagingType": "CBCT",
          "igrtMatchQuality": "Good - Shifts Applied",
          "shiftsApplied": "V: -0.2, L: 0.1, S: 0",
          "igrtApprovedBy": "RE (Physician)",
          "igrtVerificationNotes": "Minor shifts for optimal target coverage. Physician approved. Patient comfortable.",
          "patientTolerance": "Good",
          "generalSideEffects": "Mild fatigue from prior chemo.",
          "siteSpecificSideEffects": "No new GI symptoms reported today. No skin changes.",
          "painAssessment": "0/10.",
          "patientConcerns": "None.",
          "instructionsGiven": "Reinforced daily Capecitabine instructions (with food). Emphasized maintaining hydration.",
          "billingCodes": "77386, 77387",
          "dailyNotes": "Patient tolerated treatment well. No acute issues. CBCT match within protocol. Informed patient about the importance of consistent bladder filling.",
          "energiesUsed": "6MV",
          "recordedFields": [
            { "fieldName": "Field 1", "deliveredMu": 62, "notes": "OK"},
            { "fieldName": "Field 2", "deliveredMu": 78, "notes": "OK"},
            { "fieldName": "Field 3", "deliveredMu": 71, "notes": "OK"},
            { "fieldName": "Field 4", "deliveredMu": 66, "notes": "OK"},
            { "fieldName": "Field 5", "deliveredMu": 72, "notes": "OK"},
            { "fieldName": "Field 6", "deliveredMu": 77, "notes": "OK"},
            { "fieldName": "Field 7", "deliveredMu": 61, "notes": "OK"}
          ]
        },
        {
          "fractionNumber": 2,
          "totalFractions": 28,
          "date": "2025-06-02",
          "machine": "LINAC 2",
          "therapistInitials": "JG, RS",
          "overallMUs": 487,
          "setupVerification": "Tolerances Met",
          "immobilizationDevicesChecked": "BodyFix bag, abdominal compression",
          "setupAdjustments": "None",
          "organTargetChecks": "CBCT reviewed, good alignment of pancreas/target. Bowel position acceptable, outside high dose. Bladder fill consistent.",
          "imagingType": "CBCT",
          "igrtMatchQuality": "Good - No Shifts Required",
          "shiftsApplied": "None",
          "igrtApprovedBy": "Physics (Auto-match)",
          "igrtVerificationNotes": "No shifts needed today. Automated match performed by physics.",
          "patientTolerance": "Good",
          "generalSideEffects": "Mild fatigue.",
          "siteSpecificSideEffects": "No new GI symptoms.",
          "painAssessment": "0/10.",
          "patientConcerns": "Concern about appetite and occasional bloating after meals.",
          "instructionsGiven": "Encouraged small, frequent meals. Recommended nutritional supplement (Ensure) use. Discussed continued use of pancreatic enzymes.",
          "billingCodes": "77386, 77387",
          "dailyNotes": "Patient cooperative. Discussed diet with patient. CBCT match excellent. Patient continues to monitor blood glucose levels. No skin changes.",
          "energiesUsed": "6MV",
          "recordedFields": [
            { "fieldName": "Field 1", "deliveredMu": 62, "notes": "OK"},
            { "fieldName": "Field 2", "deliveredMu": 78, "notes": "OK"},
            { "fieldName": "Field 3", "deliveredMu": 71, "notes": "OK"},
            { "fieldName": "Field 4", "deliveredMu": 66, "notes": "OK"},
            { "fieldName": "Field 5", "deliveredMu": 72, "notes": "OK"},
            { "fieldName": "Field 6", "deliveredMu": 77, "notes": "OK"},
            { "fieldName": "Field 7", "deliveredMu": 61, "notes": "OK"}
          ]
        },
        {
          "fractionNumber": 3,
          "totalFractions": 28,
          "date": "2025-06-03",
          "machine": "LINAC 2",
          "therapistInitials": "MP, KL",
          "overallMUs": 487,
          "setupVerification": "Adjustments Made",
          "immobilizationDevicesChecked": "BodyFix bag, abdominal compression",
          "setupAdjustments": "V: 0.1 cm, L: 0 cm, S: 0.1 cm shifts applied based on CBCT.",
          "organTargetChecks": "CBCT reviewed, good alignment of pancreas/target. No significant bowel distension or shift into high dose area. Bladder fill noted consistent.",
          "imagingType": "CBCT",
          "igrtMatchQuality": "Good - Shifts Applied",
          "shiftsApplied": "V: 0.1, L: 0, S: 0.1",
          "igrtApprovedBy": "Physics (Auto-match)",
          "igrtVerificationNotes": "Small shift applied. Patient comfortable. Physician reviewed previous day's shifts and approved for current setup.",
          "patientTolerance": "Good",
          "generalSideEffects": "Mild fatigue, occasional mild heartburn (managed with Pantoprazole).",
          "siteSpecificSideEffects": "Reports mild abdominal discomfort after meals. No skin redness or hand-foot syndrome yet.",
          "painAssessment": "1/10 (occasional, mild).",
          "patientConcerns": "Heartburn, energy levels, concerns about future surgery.",
          "instructionsGiven": "Recommended antacids for heartburn, continue small, frequent meals, rest as needed. Reassured about surgical evaluation post-RT.",
          "billingCodes": "77386, 77387",
          "dailyNotes": "Patient remains active and cooperative. Discussed symptom management. Plan adherence good. Patient taking Capecitabine as directed. No issues with treatment delivery."
        }
      ]
    }
  },
  "imagingAndReports": [
    {
      "date": "01/20/2025",
      "type": "CT Abdomen/Pelvis w/ Contrast (Pancreas Protocol)",
      "summary": "3cm hypodense mass head of pancreas, abutting SMV. Dilated biliary ducts. Suspicious peripancreatic lymph nodes. No distant mets.",
      "reportDetails": {
        "accessionNumber": "CT-ABD-25-001",
        "protocol": "CT Abdomen and Pelvis with IV and Oral Contrast, Pancreas Protocol",
        "findings": "Hypodense, irregular mass in the head of the pancreas, measuring 3.0 x 2.8 cm, with ill-defined margins. Abuts the superior mesenteric vein (SMV) for less than 180 degrees circumference. Pancreatic duct dilation noted distal to the mass. Common bile duct dilation (1.2 cm) with abrupt cutoff at the pancreatic head. No evidence of arterial involvement (SMA, celiac). Several peripancreatic lymph nodes (up to 1.5 cm) are noted, suspicious for malignancy. No definitive liver metastases or ascites. Kidneys and spleen appear normal. No distant osseous metastases.",
        "impression": "Pancreatic head mass with regional lymphadenopathy, consistent with malignancy. Borderline resectable. Dilated biliary system. Stage IB (cT2 N0 M0 clinically based on imaging, prior to biopsy).",
        "signedBy": "Dr. A. Radiologist, 01/21/2025"
      }
    },
    {
      "date": "01/28/2025",
      "type": "CT Chest (Staging)",
      "summary": "No evidence of metastatic disease in lungs or chest lymph nodes.",
      "reportDetails": {
        "accessionNumber": "CT-Chest-25-001",
        "protocol": "CT Thorax with IV Contrast",
        "findings": "Normal lung parenchyma. No suspicious lung nodules. Mediastinal and hilar lymph nodes are not enlarged. No pleural effusion or pericardial effusion. No evidence of distant metastatic disease in the chest.",
        "impression": "No evidence of thoracic metastatic disease.",
        "signedBy": "Dr. B. Radiologist, 01/28/2025"
      }
    },
    {
      "date": "02/01/2025",
      "type": "EUS Biopsy Report",
      "summary": "Adenocarcinoma consistent with pancreatic primary. Peripancreatic lymph node negative.",
      "reportDetails": {
        "lab": "ANYTOWN HOSPITAL PATHOLOGY",
        "accessionNumber": "S25-23456",
        "specimenSource": "EUS-guided Fine Needle Aspiration (FNA) and Biopsy: 1) Pancreatic head mass, 2) Peripancreatic lymph node (Station 8a).",
        "finalDiagnosis": "1. PANCREATIC HEAD MASS, FNA AND BIOPSY: ADENOCARCINOMA, MODERATELY DIFFERENTIATED (GRADE 2).\n2. PERIPANCREATIC LYMPH NODE (STATION 8A), FNA: NEGATIVE FOR MALIGNANT CELLS.",
        "microscopicDescription": "The specimen from the pancreatic mass consists of core biopsy fragments and smears showing infiltrating glandular structures lined by atypical epithelial cells with enlarged, pleomorphic nuclei and prominent nucleoli. Mitotic figures are identified (up to 3 per 10 HPF). Desmoplastic stroma noted. The specimen from the lymph node consists of smears showing a population of benign, reactive lymphoid elements only. No malignant cells are seen.",
        "grossDescription": "Received in Cytolyt, 2 syringe washes and 1 core biopsy labeled 'Pancreatic Mass'. 1 syringe wash labeled '8a Lymph Node'.",
        "comment": "The findings are diagnostic of adenocarcinoma of the pancreas. The sampled peripancreatic lymph node shows no evidence of metastasis, which supports the clinical N0 staging. Further molecular testing may be pursued.",
        "signedBy": "Dr. C. Pathologist, 02/03/2025",
        "reviewedBy": "Dr. Mark Johnson (Med Onc)"
      }
    },
    {
      "date": "02/05/2025",
      "type": "ERCP with Stent Placement Report",
      "summary": "Successful biliary stent placement for obstruction. Jaundice relief expected.",
      "reportDetails": {
        "accessionNumber": "PROC-25-001",
        "procedure": "Endoscopic Retrograde Cholangiopancreatography (ERCP) with biliary stent placement",
        "findings": "Severe distal common bile duct stricture confirmed by cholangiogram, consistent with pancreatic head mass compression. Successful placement of a 10mm x 6cm plastic stent across the stricture. Good flow of bile demonstrated post-stent.",
        "impression": "Biliary obstruction secondary to pancreatic head mass. Stent successfully placed. Expect resolution of jaundice.",
        "signedBy": "Dr. D. Gastroenterologist, 02/05/2025"
      }
    },
    {
      "date": "05/15/2025",
      "type": "CT Abdomen/Pelvis w/ Contrast (Pancreas Protocol) - Post-Induction Chemo",
      "summary": "Interval decrease in tumor size to 2.5cm (from 3.0cm). Continued abutment of SMV (no change in vascular interface). Stable suspicious peripancreatic lymph nodes. Overall stable disease/slight response to FOLFIRINOX.",
      "reportDetails": {
        "accessionNumber": "CT-ABD-25-002",
        "protocol": "CT Abdomen and Pelvis with IV and Oral Contrast, Pancreas Protocol",
        "findings": "Pancreatic head mass measures 2.5 x 2.3 cm, slight decrease from prior 3.0 cm. Abutment of SMV for less than 180 degrees remains unchanged. No new arterial involvement. Peripancreatic lymph nodes appear stable in size. Biliary stent patent. No new liver lesions or ascites.",
        "impression": "Stable disease/slight partial response to FOLFIRINOX induction chemotherapy. Tumor remains borderline resectable. Imaging for radiation planning is suitable.",
        "signedBy": "Dr. E. Radiologist, 05/16/2025"
      }
    }
  ],
  "dicomImages": [
    {
      "description": "CT Simulation (Abdomen 4D - 05/20/2025)",
      "seriesType": "CT",
      "imageUrls": [
        "https://raw.githubusercontent.com/cornerstonejs/cornerstone-wado-image-loader/master/examples/images/CT000000.dcm"
      ],
      "ohifViewerUrl": "https://viewer.ohif.org/viewer/latest",
      "accessionNumber": "CT-20250520-ABDOMEN"
    },
    {
      "description": "Diagnostic CT Abdomen/Pelvis (Jan 20, 2025)",
      "seriesType": "CT",
      "imageUrls": [],
      "ohifViewerUrl": "https://viewer.ohif.org/viewer/latest?studyUIDs=1.3.6.1.4.1.14519.5.2.1.7009.2403.334240655099307998634586483120"
    }
  ],
  "labResults": [
    { "date": "2025-01-15", "test": "CA 19-9", "value": "1250", "units": "U/mL", "notes": "Elevated, consistent with pancreatic cancer at initial diagnosis. Normal range <35 U/mL." },
    { "date": "2025-02-15", "test": "CBC", "value": "WNL (Pre-FOLFIRINOX)", "units": "", "notes": "Baseline prior to induction chemotherapy." },
    { "date": "2025-02-15", "test": "CMP", "value": "T.Bili: 4.5 mg/dL (Elevated due to obstruction)", "units": "", "notes": "Baseline prior to induction chemotherapy. Biliary stent placed 02/05/2025." },
    { "date": "2025-05-10", "test": "CA 19-9", "value": "350", "units": "U/mL", "notes": "Significant decrease post-induction chemo, indicating response. Still elevated." },
    { "date": "2025-05-15", "test": "CBC", "value": "WBC 5.5, Hgb 12.8, Plt 250", "units": "K/uL, g/dL, K/uL", "notes": "Post-FOLFIRINOX recovery, acceptable for RT." },
    { "date": "2025-05-15", "test": "CMP", "value": "T.Bili: 0.8 mg/dL (Normal after stent)", "units": "", "notes": "Post-FOLFIRINOX recovery, T.Bili normalized after stent. Renal function good (Cr 0.9)." },
    { "date": "2025-05-28", "test": "CBC", "value": "WBC 7.2, Hgb 13.1, Plt 280", "units": "K/uL, g/dL, K/uL", "notes": "Pre-RT Baseline - Final check before starting chemoradiation. All WNL." },
    { "date": "2025-06-05", "test": "CMP (Comprehensive Metabolic Panel)", "value": "Na 138, K 4.1, Cr 0.9, Alb 3.5, T.Bili 0.8", "units": "mEq/L, mEq/L, mg/dL, g/dL, mg/dL", "notes": "Weekly check during RT - Stable electrolytes and liver function. Good hydration." },
    { "date": "2025-06-12", "test": "CBC", "value": "WBC 6.5, Hgb 12.5, Plt 240", "units": "K/uL, g/dL, K/uL", "notes": "Weekly check (Week 1 RT). Mild leukopenia from Capecitabine, acceptable. ANC 3.8 K/uL." },
    { "date": "2025-06-19", "test": "CBC", "value": "WBC 5.8, Hgb 12.1, Plt 220", "units": "K/uL, g/dL, K/uL", "notes": "Weekly check (Week 2 RT). Continued mild leukopenia. Patient asymptomatic." }
  ],
  "progressNotes": [
    { "date": "2025-05-15", "author": "Dr. Robert Evans (Rad Onc)", "type": "Initial Consult", "summary": "Patient with Borderline Resectable Pancreatic Adenocarcinoma (Head), s/p 4 cycles FOLFIRINOX with tumor response (2.5cm). Discussed multidisciplinary plan: neoadjuvant chemoradiation (IMRT 50.4Gy/28fx w/ concurrent Capecitabine) followed by surgical re-evaluation. Explained RT details, daily CBCT IGRT, motion management (4D/compression), and potential side effects (fatigue, nausea/vomiting, diarrhea, abdominal pain, skin changes). Patient agrees. CT sim scheduled. Coordinated with Med Onc for Capecitabine start. Emphasized nutritional support.", "patientTolerance": "Good", "generalSideEffects": "Mild residual fatigue from FOLFIRINOX.", "siteSpecificSideEffects": "None.", "painAssessment": "0/10 (pancreatic pain resolved with chemo).", "patientConcerns": "Concerned about further side effects after FOLFIRINOX. Asked about chances of surgery after RT.", "instructionsGiven": "Provided Pancreatic RT patient education. Reassured that RT/Capecitabine generally less toxic than FOLFIRINOX. Explained RT aims to make surgery safer/more successful." },
    { "date": "2025-05-20", "author": "Radiation Therapist Lead", "type": "Simulation Note", "summary": "4D-CT Simulation for Pancreas RT completed. Patient supine in BodyFix bag with abdominal compression. 4D-CT acquired to assess respiratory motion. Reference tattoos placed. Patient cooperative, able to maintain consistent bladder fill. Images sent to dosimetry for IMRT planning. Fusion with diagnostic CT A/P requested. Oral contrast series reviewed for bowel delineation.", "patientTolerance": "Good", "generalSideEffects": "None.", "siteSpecificSideEffects": "None.", "painAssessment": "0/10.", "patientConcerns": "Asked about need for daily imaging.", "instructionsGiven": "Explained daily CBCT ensures precise treatment delivery due to organ motion. Advised on consistent bladder filling daily before treatment." },
    { "date": "2025-06-01", "author": "Radiation Therapist", "type": "Daily Treatment Note - Fx 1", "summary": "First treatment delivered. Daily CBCT for IGRT. Patient reports taking Capecitabine as prescribed. CBCT match showed minor shifts corrected for optimal target coverage. Bowel position acceptable. Patient tolerated treatment well. Treatment time 15 minutes. Informed patient about the importance of consistent bladder filling. No acute issues. Assisted patient off table safely.", "patientTolerance": "Good", "generalSideEffects": "Mild fatigue", "siteSpecificSideEffects": "No new GI symptoms reported today. No skin changes.", "painAssessment": "0/10.", "patientConcerns": "None.", "instructionsGiven": "Reinforced daily Capecitabine instructions (with food). Emphasized maintaining hydration and nutrition." },
    { "date": "2025-06-03", "author": "Dr. Robert Evans (Rad Onc)", "type": "Oncology MD Note - Week 1", "summary": "Patient seen for weekly on-treatment visit. Completed 3/28 fx. Tolerating RT and concurrent Capecitabine well. Mild fatigue (2/10). Occasional mild heartburn, managed with OTC antacids. No significant nausea, vomiting, or diarrhea. Reports mild abdominal discomfort after meals, but overall eating well. Continue plan as prescribed. Reviewed weekly labs (WBC 6.5, Plt 240k, Cr 0.9) - all acceptable. Reminded patient about nutritional counseling.", "patientTolerance": "Good", "generalSideEffects": "Mild fatigue, occasional mild heartburn.", "siteSpecificSideEffects": "Mild abdominal discomfort after meals.", "painAssessment": "1/10 (occasional).", "patientConcerns": "Heartburn, energy levels, and concerns about appetite.", "instructionsGiven": "Recommended antacids for heartburn, continue small, frequent meals, rest as needed. Encouraged continued use of pancreatic enzymes." },
    { "date": "2025-06-10", "author": "Dr. Robert Evans (Rad Onc)", "type": "Oncology MD Note - Week 2", "summary": "Patient completed 8/28 fx. Reports mild increase in fatigue (3/10) and occasional mild nausea (Grade 1), well-controlled with Ondansetron. Abdominal discomfort stable. Labs (WBC 5.8, Plt 220k, Cr 0.9) - all acceptable. Continue RT/Capecitabine. Reinforce hydration. Discussed importance of consistent bladder filling. No skin changes noted. Patient very cooperative with daily CBCTs.", "patientTolerance": "Good", "generalSideEffects": "Mild fatigue, occasional nausea.", "siteSpecificSideEffects": "Mild abdominal discomfort after meals.", "painAssessment": "1/10 (occasional).", "patientConcerns": "Asked about potential skin redness and hand-foot syndrome from Capecitabine.", "instructionsGiven": "Advised on proactive skin moisturization for hand-foot syndrome. Reassured that skin redness from RT is less common on abdomen. Encourage regular use of anti-nausea meds." },
    { "date": "2025-06-17", "author": "Dr. Robert Evans (Rad Onc)", "type": "Oncology MD Note - Week 3", "summary": "Patient completed 13/28 fx. Fatigue moderate (4/10). Mild intermittent diarrhea (Grade 1), managed with Loperamide. Abdominal discomfort stable. Labs (WBC 5.0, Plt 200k, Cr 1.0) - acceptable. Skin on abdomen/pelvis remains intact. Continue RT/Capecitabine. Patient is a good candidate for adaptive planning given the daily CBCTs. Discussed upcoming repeat CT simulation for adaptive planning.", "patientTolerance": "Fair", "generalSideEffects": "Moderate fatigue, mild intermittent diarrhea.", "siteSpecificSideEffects": "Mild abdominal discomfort.", "painAssessment": "1/10 (occasional).", "patientConcerns": "Reports mild diarrhea. Asked about repeat CT scan next week.", "instructionsGiven": "Reinforced Loperamide use. Explained repeat CT is to ensure target coverage and organ sparing are optimized as patient changes over treatment course. Advised patient that overall treatment time will remain the same. Re-reviewed nutritional goals." }
  ],
  "patientEducation": {
    "goalsDiscussed": "Neoadjuvant chemoradiation aims to shrink the pancreatic tumor and involved lymph nodes, potentially making surgery (Whipple procedure) more feasible and increasing the chance of clear surgical margins. This is a crucial step towards curative intent. Radiation (IMRT) targets the tumor precisely, and concurrent oral chemotherapy (Capecitabine) enhances radiation effectiveness.",
    "sideEffectsReviewed": "Common: Fatigue (can range from mild to moderate, especially mid-course), gastrointestinal side effects (nausea, vomiting, diarrhea, abdominal pain/cramping, heartburn, appetite changes), skin irritation (erythema, dry desquamation in treatment field, less common with IMRT but still possible), myelosuppression (low blood counts, less common with Capecitabine than IV chemo, but monitored). Specific to Capecitabine: Hand-foot syndrome (redness, tenderness, peeling on palms/soles). Specific to RT: Radiation enteritis (inflammation of small bowel/colon), gastritis (stomach inflammation), liver/kidney changes (minimized with careful planning). Diabetes management may require adjustments.",
    "safetyConsiderations": "Critical: **Consistent daily positioning** on the treatment table is vital, including proper immobilization and maintaining a consistent bladder fill for daily CBCT imaging. This ensures accurate dose delivery and organ sparing. Reporting any new or worsening symptoms promptly, especially fever (>100.4Â°F), severe abdominal pain, persistent nausea/vomiting, significant diarrhea, or any bleeding. Careful monitoring of blood glucose levels due to diabetes. Adherence to prescribed medications for symptom management is key.",
    "patientResponsibilities": "Attend all daily RT appointments. Take oral Capecitabine exactly as prescribed (with food). Maintain consistent bladder fullness before each daily treatment. Perform daily skin care as instructed. Report all symptoms promptly (especially GI issues, hand-foot changes, fatigue). Maintain good hydration and nutrition (frequent small meals, nutritional supplements if needed). Continue monitoring blood glucose levels and adjusting diabetes medications with your endocrinologist/PCP as advised.",
    "medicationCompliance": "Reinforced importance of taking Capecitabine exactly as prescribed (timing with meals). Proactive use of anti-nausea and anti-diarrhea medications. Regular use of pancreatic enzymes with all meals/snacks. Consistent use of antacids/PPI for heartburn. Discuss any medication side effects or challenges with the care team immediately."
  },
  "scheduling": [
    { "date": "2025-02-01", "type": "EUS Biopsy (Pancreas Head)", "location": "Endoscopy Suite", "status": "Completed" },
    { "date": "2025-02-05", "type": "ERCP with Biliary Stent Placement", "location": "Endoscopy Suite", "status": "Completed" },
    { "date": "2025-02-15 - 2025-05-10", "type": "Induction Chemotherapy (FOLFIRINOX - 4 cycles)", "location": "Medical Oncology Infusion Center", "status": "Completed" },
    { "date": "2025-05-15", "type": "Multidisciplinary Tumor Board Review", "location": "Conference Room A", "status": "Completed" },
    { "date": "2025-05-15", "type": "Rad Onc Consult", "location": "Radiation Oncology Clinic - Exam Room 1", "status": "Completed" },
    { "date": "2025-05-20", "type": "4D-CT Simulation Abdomen/Pancreas", "location": "Radiation Oncology Sim Room", "status": "Completed" },
    { "date": "2025-06-01", "type": "First Treatment (Fx 1/28) & Capecitabine Start", "location": "Linear Accelerator #2", "status": "Completed" },
    { "date": "2025-06-03", "type": "Oncology MD Visit (Week 1 RT)", "location": "Oncology Clinic, Room 3", "status": "Completed" },
    { "date": "2025-06-10", "type": "Oncology MD Visit (Week 2 RT)", "location": "Oncology Clinic, Room 3", "status": "Completed" },
    { "date": "2025-06-17", "type": "Oncology MD Visit (Week 3 RT) & Adaptive CT Sim Consult", "location": "Oncology Clinic, Room 3", "status": "Completed" },
    { "date": "2025-06-25", "type": "CT Simulation (Repeat for Adaptive Plan)", "location": "Radiation Oncology Sim Room", "status": "Scheduled", "notes": "Planned re-simulation for adaptive planning." },
    { "date": "2025-07-01", "type": "Oncology MD Visit (Week 5 RT)", "location": "Oncology Clinic, Room 3", "status": "Scheduled" },
    { "date": "2025-07-16", "type": "End of Treatment (Fx 28/28)", "location": "Linear Accelerator #2", "status": "Scheduled" },
    { "date": "2025-08-15", "type": "Surgical Consult (Post-ChemoRT Re-eval)", "location": "HPB Surgery Clinic", "status": "Scheduled" },
    { "date": "2025-08-20", "type": "Post-ChemoRT PET/CT Scan", "location": "Imaging Department", "status": "Scheduled" }
  ],
  "cptCharges": [
    { "code": "77290", "description": "Simulation, Complex (4D-CT Abdomen/Pancreas)", "frequency": "Once (Initial) + Once (Re-sim)" },
    { "code": "77334", "description": "Treatment device, Complex (BodyFix/VacLok bag, abdominal compression)", "frequency": "Once per course" },
    { "code": "77301", "description": "IMRT planning", "frequency": "Once (Initial) + Once (Adaptive Plan)" },
    { "code": "77386", "description": "Intensity modulated radiation treatment delivery, complex", "frequency": "Daily (28 total fractions)" },
    { "code": "77387", "description": "Image Guided RT (IGRT) - Daily CBCT with soft tissue match", "frequency": "Daily (28 total fractions)" },
    { "code": "77427", "description": "Radiation treatment management, 5 treatments", "frequency": "Weekly (6 total visits for 28 fractions)" },
    { "code": "99214", "description": "Office or other outpatient visit, established patient (for weekly MD visits)", "frequency": "Weekly (6 visits)" }
  ],
  "diagnosisSearch": "Pancreatic Cancer, Adenocarcinoma, Borderline Resectable"
}
